Commercialisation agreement for Canberra's synthetic catalyst
11 June, 2015A commercialisation deal for a new synthetic catalyst will help make the pharmaceutical manufacturing process more efficient, particularly in the production of ADD/ADHD drug Ritalin (methylphenidate).
Phosphagenics appoints consultant for promoting drug delivery tech
09 June, 2015Phosphagenics (ASX:POH) has engaged the services of Dr Steve Meller to assist the company in partnering its TPM (Targeted Penetration Matrix) drug delivery technology with large companies selling into the mass market.
Clinical Network Services is Australia's favourite CRO
09 June, 2015Clinical Network Services (CNS), an integrated service group focused on clinical product development, has been announced as Australia's favourite CRO for 2015 by ARCS Australia.
Partnership and Early Access Program for Antisense
01 June, 2015Melbourne biotech Antisense Therapeutics (ASX:ANP) has announced an Early Access Program (EAP) for its multiple sclerosis (MS) therapy ATL1102 in the European Union, as well as a partnership with a US-based company to develop its growth disorder treatment ATL1103.
Orphan designation for Huntington's candidate
01 June, 2015Prana Biotechnology has announced that the European Commission has approved orphan designation for its lead drug candidate, PBT2, for the treatment of Huntington's disease.
New Cochlear CEO appointed
26 May, 2015Chris Smith has been announced as the incoming CEO and president of Cochlear Limited (ASX:COH). He will become the company's deputy CEO from 1 July and relocate to Sydney to take up the CEO position as of 1 September.
GSK granted $1 million for advanced manufacturing project
21 May, 2015Healthcare company GSK Australia has received a $1 million grant through the federal government's Manufacturing Transition Programme. The funding will support GSK's advanced manufacturing expansion plans at its Boronia site in Melbourne's outer-eastern suburbs.
Reformulation required for Phosphagenics pain patch
14 May, 2015 by Lauren DavisIt's been a less-than-ideal week for drug delivery company Phosphagenics (ASX:POH), which will soon be reformulating its TPM/Oxymorphone patch and beginning the search for a new chairman.
Europe agrees to blow the green whistle
09 May, 2015 by Lauren DavisThe Australian-invented painkiller Penthrox - commonly known as the 'green whistle' - has received initial regulatory approval for sale in the UK and Europe.
Drawbridge anaesthetic trial accepted for publication
07 May, 2015 by Lauren DavisDrawbridge Pharmaceuticals has announced the imminent publication of its phase 1c proof-of-concept clinical trial of Phaxan, a fast onset and offset intravenous general anaesthetic and sedative, in the medical journal Anesthesia and Analgesia.
2014 a good year for licensing transactions, says MoFo
04 May, 2015Law firm Morrison & Foerster's latest BioMeter report, recapping upfront licensing transactions among life sciences companies for all of 2014, confirms strong industry momentum which is said to be continuing into the current year.
$200 million for Medical Research Commercialisation Fund
21 April, 2015Brandon Capital Partners, the manager of the Medical Research Commercialisation Fund (MRCF), has announced the closing of a $200 million life science venture capital fund - Australia's largest ever life science venture fund.
Pain trial dosing and new directors at Phosphagenics
18 April, 2015Phosphagenics has commenced dosing in a phase 2 clinical trial investigating the safety and efficacy of the drug delivery company's TPM/oxycodone patch in patients suffering post-herpetic neuralgia (PHN), a complication of shingles.
Adam Kelliher announced as Avita Medical CEO
14 April, 2015Regenerative medicine company Avita Medical (ASX:AVH) has announced entrepreneur Adam Kelliher as its new chief executive officer.
Bacteria-resistant catheters to reduce infection
16 March, 2015Flinders University researchers are undertaking a project to reduce urinary tract infections associated with the use of catheters during hospital stays.
